Literature DB >> 21737236

Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis.

Giorgio Berlot1, Michele C Vassallo, Nicola Busetto, Monica Bianchi, Francesca Zornada, Ivana Rosato, Fabiana Tartamella, Lara Prisco, Federica Bigotto, Tiziana Bigolin, Massimo Ferluga, Irene Batticci, Enrico Michelone, Massimo Borelli, Marino Viviani, Ariella Tomasini.   

Abstract

PURPOSE: Because the use of IgM and IgA enriched polyclonal intravenous immunoglobulins (eIg) is a standard of care in critically ill patients admitted to our intensive care unit (ICU) with the diagnosis of severe sepsis or septic shock, we investigated if the delay from the onset of severe sepsis and septic shock and their administration could influence the outcome.
MATERIALS AND METHODS: The medical records of all patients with severe sepsis or septic shock admitted to our ICU from July 2004 through October 2009 and treated with eIg (Pentaglobin®; Biotest, Dreieich, Germany) were retrospectively examined.
RESULTS: A total of 129 adult patients with severe sepsis or septic shock were considered eligible. Thirty-two percent of patients died during the ICU stay. Survivors were given eIg significantly earlier than nonsurvivors (23 vs 63 hours, P < .05). The delay in the administration of eIg and the Simplified Acute Physiology Score II were the only variables that entered stepwise a propensity score-adjusted logistic model. The delay in the administration of eIg was a significant predictor of the odds of dying during the ICU stay (odds ratio for 1 hour of delay, 1.007; P < .01; 99% confidence interval from 1.001 to 1.010) and proved to be independent from the Simplified Acute Physiology Score II and other variables.
CONCLUSIONS: The efficacy of eIg, being maximal in early phases of severe sepsis and/or septic shock, is probably time dependent.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737236     DOI: 10.1016/j.jcrc.2011.05.012

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

1.  The Japanese guidelines for the management of sepsis.

Authors:  Shigeto Oda; Mayuki Aibiki; Toshiaki Ikeda; Hitoshi Imaizumi; Shigeatsu Endo; Ryoichi Ochiai; Joji Kotani; Nobuaki Shime; Osamu Nishida; Takayuki Noguchi; Naoyuki Matsuda; Hiroyuki Hirasawa
Journal:  J Intensive Care       Date:  2014-10-28

Review 2.  Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.

Authors:  Christine S Cocanour; Phillip Chang; Jared M Huston; Charles A Adams; Jose J Diaz; Charles B Wessel; Bonnie A Falcione; Graciela M Bauza; Raquel A Forsythe; Matthew R Rosengart
Journal:  Surg Infect (Larchmt)       Date:  2017-04-04       Impact factor: 2.150

3.  IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens.

Authors:  Paul J Maglione; Noa Simchoni; Samuel Black; Lin Radigan; Jessica R Overbey; Emilia Bagiella; James B Bussel; Xavier Bossuyt; Jean-Laurent Casanova; Isabelle Meyts; Andrea Cerutti; Capucine Picard; Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

4.  Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study.

Authors:  Ildiko Toth; Andras Mikor; Tamas Leiner; Zsolt Molnar; Lajos Bogar; Tamas Szakmany
Journal:  J Anesth       Date:  2013-01-12       Impact factor: 2.078

5.  Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock.

Authors:  Ilaria Cavazzuti; Giulia Serafini; Stefano Busani; Laura Rinaldi; Emanuela Biagioni; Marta Buoncristiano; Massimo Girardis
Journal:  Intensive Care Med       Date:  2014-09-13       Impact factor: 17.440

6.  The original sins of clinical trials with intravenous immunoglobulins in sepsis.

Authors:  Raquel Almansa; Eduardo Tamayo; David Andaluz-Ojeda; Leonor Nogales; Jesús Blanco; Jose Maria Eiros; Jose Ignacio Gomez-Herreras; Jesus F Bermejo-Martin
Journal:  Crit Care       Date:  2015-02-26       Impact factor: 9.097

7.  In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.

Authors:  F S Rossmann; A Kropec; D Laverde; F R Saaverda; D Wobser; J Huebner
Journal:  Infection       Date:  2014-11-27       Impact factor: 3.553

8.  IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation.

Authors:  Jeroen D Langereis; Stefanie S Henriet; Saskia Kuipers; Corry M R Weemaes; Mirjam van der Burg; Marien I de Jonge; Michiel van der Flier
Journal:  J Clin Immunol       Date:  2018-01-15       Impact factor: 8.317

Review 9.  Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

10.  Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study).

Authors:  Emin Abdullayev; Omer Kilic; Gurkan Bozan; Eylem Kiral; Merve Iseri Nepesov; Ener Cagri Dinleyici
Journal:  Hum Vaccin Immunother       Date:  2020-02-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.